(Q38103645)

28 August 2017

Relapsed childhood acute lymphoblastic leukaemia (English)

1 reference

28 August 2017

1 reference

2

Ching-Hon Pui

1 reference

28 August 2017

Deepa Bhojwani

1

1 reference

28 August 2017

1 May 2013

1 reference

Lancet Oncology Commission

28 August 2017

1 reference

28 August 2017

14

1 reference

28 August 2017

6

1 reference

28 August 2017

e205-17

1 reference

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

JAK mutations in high-risk childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children's Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

ETV6/RUNX1-positive relapses evolve from an ancestral clone and frequently acquire deletions of genes implicated in glucocorticoid signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Clonal origins of relapse in ETV6-RUNX1 acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

CREBBP mutations in relapsed acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Bone-marrow relapse in paediatric acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

How I treat relapsed childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Outcome after first relapse in children with acute lymphoblastic leukemia: a report based on the Dutch Childhood Oncology Group (DCOG) relapse all 98 protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Mar

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Treatment of childhood acute lymphoblastic leukemia in second remission with allogeneic bone marrow transplantation and chemotherapy: ten-year experience of the Italian Bone Marrow Transplantation Group and the Italian Pediatric Hematology Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Haploidentical stem cell transplantation for children with high-risk leukemia.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Current management and challenges of malignant disease in the CNS in paediatric leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Comm

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

First isolated extramedullary relapse in children with B-cell precursor acute lymphoblastic leukaemia: results of the Cooprall-97 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Treatment of isolated testicular recurrence of acute lymphoblastic leukemia without radiotherapy. Report from the Dutch Late Effects Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Intrathecal liposomal cytarabine: more friend than foe?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Natural killer cell engineering for cellular therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Use of NK cell activity in cure by transplant

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Good clinical practice and the conduct of clinical studies in pediatric oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970580-6

7 January 2021

10.1016/S1470-2045(12)70580-6

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23639321